
FDA Lifts Clinical Hold on Tabelecleucel Trial for EBV+ Post-Transplant Lymphoproliferative Disease
The FDA has lifted the clinical hold on an active investigational new drug application for the tabelecleucel (Ebvallo), allowing the resumption of clinical research for patients with Epstein-Barr virus (EBV)–positive post-transplant lymphoproliferative …